Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia (RedLANO registry).

Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

“…The standard of care for newly diagnosed GBM patients aged ≤70 years has been established by the EORTC/NCIC 3 trial, and 72.8% of cases considered in the present study underwent this treatment protocol (Table 1). Our survival data are comparable with those obtained in the EORTC/NCIC trial and the more recent RTOG 0525 trial, 9 as well data obtained in retrospective registries in North America (United States and Canada) 10,11 and South America (Columbia), 12 and seem better than data from Austria 13 and Switzerland. 14 In particular, these results are comparable with those reported in the retrospective Surveillance, Epidemiology and End Results (SEER) program, 6 in which 65% of patients received the combined treatment according to EORTC/NCIC, followed by an OS of 15 months; 23% of patients who received no postsurgical treatment had an OS of 2 months.…”

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review

“…Among these, 351 articles were excluded after title screening and the abstract of the 784 remaining papers was assessed. Finally, 461 publications were excluded following the eligibility criteria and thus, 323 articles that had interpretable data and fulfilled the eligibility criteria were used for data extraction…”

“…In addition to the oncology databases, there were registries identified in diseases including heart failure (RECODEC 290,291 and ROCI 308 registries), trauma, 180,183,184,208,309 infectious diseases (GREBO 90,311,312 healthcare workers occupational exposure registry 192 ), and glomerulonephritis (Nefrored 174,177,188 ), among others 37,146,185,187,192,220,238,255,264 …”